Search Results
Your search for ,had matches 18486 pages
Showing 13101 - 13150AUA 2016: Relationship Between Testosterone Therapy and Prostate Cancer Explored
Men with low levels of the male sex hormone testosterone need not fear that testosterone replacement therapy will increase their risk of prostate cancer. This is the finding of an analysis of more than a quarter-million medical records of mostly white men in Sweden, research led by investigators at ...
Hormone Combination Therapy May Increase Risk of Breast Cancer in African American Women
The use of combination therapy with estrogen plus progestin, previously shown to be associated with an increased incidence of estrogen receptor–positive breast cancer in postmenopausal women in studies based largely on white women, has been shown to increase estrogen receptor–positive breast cancer ...
Improved Survival With Shorter Delays Between Diagnosis and Surgery and Before Initiating Adjuvant Chemotherapy
The survival benefits of reducing the time to surgery following a diagnosis of breast cancer and the time to initiation of adjuvant chemotherapy following surgery were outlined in two articles and an accompanying editorial in JAMA Oncology. Analyzing two independent population-based studies with a...
Corporate Angel Network’s 50,000th Patient Flight Benefits Young Retinoblastoma Patient
On April 14, 2016, an 18-month-old patient with cancer named Baron Yerby flew home to Atlanta after receiving treatment at Memorial Sloan Kettering Cancer Center. However, instead of flying on a crowded commercial plane with the potential for immune deficiency issues, he and his parents flew on a...
Cancer Stole My Identity
In 1997, just 6 weeks after giving birth to my second child, I started having fevers and night sweats and my lymph nodes were swollen. I’m a physician, so I knew something was wrong and that my symptoms were unrelated to having just given birth. I had a blood test, and a biopsy was performed on one ...
‘So How Long Do I Have?’
Imagine accidentally falling off an abyss. One simply cannot fully understand the gravity of the situation! You might skip a beat thinking about it while sitting in a chair in your living room, if you have tons of empathy, as you try to get into the shoes that are flailing for survival. But there...
A History of Medical Care for the Dying
In 2006, palliative care became a board-certified subspecialty of internal medicine, with specialized fellowships for physicians interested in the field. Despite its formal integration into best practices medical care, about 70% of Americans describe themselves as “not at all knowledgeable” about ...
Inspirational Stories for Cancer Survivors
Surveys indicate that cancer survivors have varying desires regarding the kind of support they want. Some patients find support groups very helpful as they deal with the host of issues in survivorship. Others want to distance themselves from the “world of cancer.” Studies also show that...
Breakthrough Therapy Efforts Result in Unprecedented Success
Friends of Cancer Research (Friends) and the U.S. Food and Drug Administration (FDA) have been working together for many years on an idea known as breakthrough therapy, and it has produced results beyond anyone’s hopes. Said Ellen Sigal, PhD, Friends Chair and Founder, “When we were first talking...
Clinical Trials Actively Recruiting Patients With Ewing Sarcoma
Phase I Study Title: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy-Refractory Ewing Sarcoma Study Type: Interventional/nonrandomized/single-group assignment Study Sponsor and Collaborators: University of Louisville Purpose: To examine the...
Recurrences Observed in More Than 50% of Inadequately Treated Patients With Ductal Carcinoma in Situ
A mid much debate about the potential for overly aggressive treatment of ductal carcinoma in situ comes a study that gives one pause. According to research presented at the 17th Annual Meeting of the American Society of Breast Surgeons, more than half of all women with ductal carcinoma in situ that ...
AUA 2016: Cell-Cycle Progression Score Provides Significant Prognostic Information in Patients With Gleason Score < 7
Myriad Genetics announced results from a study of the prognostic information provided by its Prolaris test in patients with prostate cancer and a Gleason score < 7 at the 111th Annual Scientific Meeting of the American Urological Association (AUA) (Abstract MP02-20). Prolaris is a novel 46-gene ...
AUA 2016: BRCA Gene Mutations Associated With Increased Prostate Cancer Risk
Though predominantly known for their increased associations with breast cancer risk, germline mutations in the BRCA1 and BRCA2 genes are also associated with an increased susceptibility to other diseases, including prostate cancer. New data being presented during the 111th Annual Scientific Meeting ...
AUA 2016: Adjuvant Chemotherapy After Radical Prostatectomy May Benefit Men at High Risk for Relapse
Not all men with prostate cancer benefit from adjuvant chemotherapy after radical prostatectomy; however, African American men and men with a higher tumor stage may, according to a new U.S. Department of Veterans Affairs (VA) study (Abstract PI LBA 06) featured at the 111th Annual Scientific...
Risk Factors for Acute Pancreatitis in Children/Young Adults With Acute Lymphoblastic Leukemia
In a study reported in the Journal of Clinical Oncology, Liu et al found that Native American ancestry, older age, higher cumulative dose of asparaginase, and a rare variant of the CPA2 gene increased risk for pancreatitis in children/young adults with acute lymphoblastic leukemia (ALL). Study...
Benefit of Dexamethasone and High-Dose Methotrexate in Children/Young Adults With High-Risk B-Acute Lymphoblastic Leukemia
As reported by Larsen et al in the Journal of Clinical Oncology, final data from the Children’s Oncology Group (COG) AALL0232 trial indicate that the event-free survival benefit of high-dose methotrexate was maintained in children/young adults with high-risk B-acute lymphoblastic leukemia....
Defibrotide Sodium for Hepatic Veno-occlusive Disease After HSCT
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 30, 2016, defibrotide sodium (Defitelio) was approved for...
Shedding Light on a Cornucopia of Breast Tumor Biomarker Assays
As our understanding of the complexities of breast cancer expands, so does our treatment armamentarium—and along with it the range of factors that must be included in our treatment decisions. Gone is the simple algorithm of adjuvant chemotherapy for almost every patient with a ≥ 2-cm tumor, except...
ASCO Guideline on Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer
As reported in the Journal of Clinical Oncology by Lyndsay N. Harris, MD, and colleagues,1 ASCO has released a clinical practice guideline on the use of biomarkers in addition to estrogen receptor/progesterone receptor and HER2 status to guide decisions on adjuvant systemic therapy in women with...
Moving Forward in Castration-Resistant Prostate Cancer: The TERRAIN and STRIVE Studies
It was over 2 decades ago that my colleagues and I reported in The New England Journal of Medicine that a first-generation oral antiandrogen, flutamide, when added to a luteinizing hormone–releasing hormone (LHRH) agonist, improved survival by nearly 6 months compared to an LHRH agonist alone in...
Enzalutamide Produces Large Progression-Free Survival Benefit vs Bicalutamide in Two Trials in Castration-Resistant Prostate Cancer
In the randomized phase II TERRAIN trial reported in The Lancet Oncology, Neal D. Shore, MD, of Carolina Urologic Research Center, Myrtle Beach, and colleagues found that use of the androgen receptor inhibitor enzalutamide (Xtandi) more than doubled median progression-free survival vs bicalutamide...
Breaking Down Dogma With the Outgoing President of SGO
At the 2016 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, The ASCO Post sat down with the SGO’s outgoing President, Robert L. Coleman, MD, and discussed the revolutionary potential of blood biomarkers, why enhanced recovery after surgery protocols is a significant...
Robert Weinberg, PhD, Receives AACR Award for Lifetime Achievement in Cancer Research
Robert Weinberg, PhD, was honored for his seminal contributions to cancer research and cancer biology with the 13th annual American Association for Cancer Research (AACR) Award for Lifetime Achievement in Cancer Research at the 2016 AACR Annual Meeting, held in New Orleans, April 16–20. The AACR...
Waun Ki Hong, MD, Receives 10th AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
The American Association for Cancer Research (AACR) honored Waun Ki Hong, MD, with the 10th annual Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the 2016 AACR Annual Meeting, held in New Orleans, April 16–20. The Margaret Foti Award for Leadership and...
FDA Approves Cabozantinib in Patients With Renal Cell Carcinoma Who Have Received Prior Antiangiogenic Therapy
On April 25, 2016, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. Cabozantinib is a dual tyrosine kinase inhibitor of MET and VEGFR2. The capsule...
Roundup of Ovarian Cancer Abstracts From 2016 SGO Annual Meeting on Women’s Cancer
At the 2016 Society of Gynecologic Oncology’s (SOG’s) Annual Meeting on Women’s Cancer, Thomas J. Herzog, MD, Clinical Director, University of Cincinnati (UC) Cancer Institute and Professor of Obstetrics and Gynecology at UC College of Medicine, provided commentary on several noteworthy ovarian...
Expert Point of View: Gini Fleming, MD
In the discussion session, Gini Fleming, MD, Professor of Medicine and Director of the Gynecologic Oncology and Medical Oncology Breast Program at the University of Chicago Medical Center, analyzed the three previous, large trials on which the presumed benefits of intraperitoneal therapy in women...
Intraperitoneal Chemotherapy in Question in Ovarian Cancers
A phase III trial of bevacizumab (Avastin) with intravenous vs intraperitoneal chemotherapy showed no improvement in progression-free survival for first-line treatment of patients with optimally surgically resected stage II and III ovarian, peritoneal, or fallopian tube cancer.1 When compared with...
Selected Abstracts From the 2016 BMT Tandem Meetings
The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research and the American Society of Blood and Marrow Transplantation. Held recently in Honolulu, Hawaii, this year’s BMT Tandem Meetings drew 3,000 attendees from 35 countries,...
Expert Point of View: Harold Burstein, MD, PhD
Invited discussant Harold Burstein, MD, PhD, Associate Professor of Medicine at Harvard Medical School and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women’s Hospital, Boston, called MINDACT “a heroic effort” whose results show that combining stage, pathology, and...
First Results From MINDACT Confirm the Benefit of Genomic Profiling
The primary analysis of the MINDACT trial confirms the value of genomic profiling for patients with early breast cancer with zero to three positive lymph nodes, according to MINDACT investigators and breast cancer specialists who heard the results at the 2016 American Association of Cancer Research ...
Nivolumab: New Standard of Care for Progressive Head and Neck Cancer After Platinum Therapy
Squamous cell carcinoma of the head and neck that progresses after platinum-based therapy has a dismal prognosis, and there is no effective standard of care. No treatment has improved survival for this patient population, but that may be about to change. Nivolumab (Opdivo), an anti–PD-1 (programmed ...
Using Telemedicine to Reduce Wait Times for Veterans
John Farrow, a 67-year-old Vietnam veteran, had not been able to sleep for days. A week ago, his primary care doctor at his local outpatient Veterans Administration (VA) clinic told him that his prostate-specific antigen (PSA) blood level was rapidly increasing, and his prostate was abnormal on...
Making the Moonshot Initiative a Reality
Excitement was high on the last day of the 2016 Annual Meeting of the American Association for Cancer Research (AACR) in anticipation of Vice President Joseph R. Biden’s remarks related to the Moonshot Initiative to accelerate progress in cancer research. The Secret Service made elaborate...
One-Third of Patients With Advanced Melanoma Survive at Least 5 Years After Nivolumab Treatment
The news is good from the longest follow-up survival study of patients with advanced melanoma who were treated with the anti–programmed cell death protein 1 (PD-1) agent nivolumab (Opdivo).1 Thirty-four percent of patients who received the drug in a phase I trial (CA909-003) were alive 5 years...
Early Study Looks to Achieve Chloride Homeostasis Through Gene Transfer to Alleviate Cancer-Related Neuropathic Pain
A study providing new information about neuropathic pain afflicting some 90% of cancer patients who have had nerve damage caused by tumors, surgery, chemotherapy, or radiation indicates gene therapy as a possible treatment. The study in rats showed transfer of a gene known as KCC2 into the spinal...
Study Finds Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals
As reported by Vasen et al in the Journal of Clinical Oncology, surveillance for pancreatic ductal adenocarcinoma in high-risk individuals appears to be of benefit in individuals at risk due to CDKN2A mutation, with the advantage being less clear among individuals at risk due to familial clustering ...
Little Apparent Activity of Cetuximab in Refractory Metastatic Colorectal Cancer With KRAS G13D Mutation
Cetuximab (Erbitux) exhibited little apparent activity in refractory metastatic colorectal cancer harboring the KRAS G13D mutation, according to the findings of the phase II Australasian Gastro-Intestinal Trials Group ICECREAM study, which were reported by Segelov et al in the Journal of Clinical...
Spectrin Gene Identified as a Biomarker in HPV-Negative Oral Cavity Squamous Cell Carcinoma
Researchers have identified a gene that may help to predict survival outcomes in patients with cancer of the mouth and tongue. Patients whose tumors express a gene called spectrin are 4.6 times more likely to die at any given time, according to a study by researchers at Loyola Medicine and Loyola...
Potential Targets for Loss of Appetite/Cachexia Related to Interleukin 18 Activity Identified in Early Studies
Loss of appetite during illness is a common and potentially debilitating phenomenon. In cancer patients especially, it can even shorten lifespan. Scientists at The Scripps Research Institute (TSRI) have discovered how an immune system molecule controls a brain circuit and reduces appetite. Their...
Assessing the Accuracy and Readability of Online Health Information for Patients With Pancreatic Cancer
Online information on pancreatic cancer overestimates the reading ability of the overall population and lacks accurate information about alternative therapy, according to a study published by Storino et al in JAMA Surgery. The degree to which patients are empowered by written educational materials ...
Trastuzumab/Lapatinib Active in Refractory, KRAS Codon 12/13 Wild-Type, HER2-Positive Metastatic Colorectal Cancer
Dual HER2 inhibition with trastuzumab (Herceptin) and lapatinib (Tykerb) was active in patients with refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer, according to an Italian phase II trial reported by Sartore-Bianchi et al in The Lancet Oncology. Study Details...
Pembrolizumab Active in Virus-Positive and ‑Negative Advanced Merkel Cell Carcinoma
The PD-1 (programmed cell death protein 1) inhibitor pembrolizumab (Keytruda) was active in advanced Merkel cell carcinoma in both Merkel cell polyomavirus (MCP)-positive and -negative tumors, according to Nghiem et al, who reported their phase II study findings in The New England Journal of...
FDA Grants sBLA for Blinatumomab in Pediatric Patients With Ph–Negative Relapsed/Refractory B-Cell Precursor ALL
Amgen announced on May 3 that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for blinatumomab (Blincyto) to include new data supporting the treatment of pediatric and adolescent patients with Philadelphia...
Similar Outcomes Reported With ABVD vs BEACOPP in High-Risk Advanced Hodgkin Lymphoma
In a phase III trial (EORTC 20012 Intergroup Trial) reported by Carde et al in the Journal of Clinical Oncology, similar outcomes were achieved with eight cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) vs four cycles each of escalated BEACOPP (bleomycin, etoposide, doxorubicin,...
Effects of High Residential Segregation and Neighborhood Characteristics on Early-Stage NSCLC Surgery
Black residents of highly segregated neighborhoods were less likely to receive surgery for early-stage non–small cell lung cancer (NSCLC) than their peers in less-segregated neighborhoods, according to a study published by Johnson et al in Cancer Epidemiology, Biomarkers & Prevention....
ESTRO 2016: New Study Sheds Light on Mastectomy vs Breast-Conserving Therapy in Older vs Younger Patients With Early Breast Cancer
New research presented at the ESTRO 35 Conference on April 30 (Abstract OC-0052) has shown women aged younger than 45 years with early-stage breast cancer that had not spread to the lymph nodes and who opted for breast-conserving therapy with radiation therapy had a 13% higher risk of developing a...
ESTRO 2016: Radiotherapy vs Chemotherapy in a Study of Patients With Early Stage II Testicular Cancer
A large study of testicular cancer patients showed that radiation therapy was more effective than chemotherapy for patients with stage IIa disease (where one or more regional lymph nodes contain cancer cells, but they are less than 2 cm in diameter). These findings, presented at the ESTRO 35...
Study Finds Cancer Mortality Risks From Long-Term Exposure to Ambient Fine Particulate Matter
Long-term exposure to ambient fine particulate matter, a mixture of environmental pollutants, was associated with increased risk of mortality for many types of cancer in an elderly Hong Kong population, according to a study published by Wong et al in Cancer Epidemiology, Biomarkers &...
ESTRO 2016: SBRT in Early-Stage Lung Cancer Linked to Increased Risk of Noncancer Deaths
Researchers have found that treating patients who have early-stage non–small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) is associated with a small but increased risk of death from causes other than cancer, according to findings presented at the European Society...
